HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc07-0545v1 30/11/2800    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Albert, S. G. Articles by McPherson, T. Search for Related Content PubMed PubMed Citation Articles by Albert, S. G. Articles by McPherson, T. Social Bookmarking                What's this?

The Effect of Glucosamine on Serum HDL Cholesterol and Apolipoprotein AI Levels in People With Diabetes

¹ Department of Internal Medicine, Division of Endocrinology, Saint Louis University School of Medicine, St. Louis, Missouri
² Department of Medicine, University of Florida, Jacksonville, Florida
³ Department of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, Illinois

Address correspondence and reprint requests to Stewart G. Albert, MD, Internal Medicine, Division of Endocrinology, Saint Louis University School of Medicine, 1402 South Grand Blvd., St. Louis, MO 63104. E-mail: albertsg{at}slu.edu

OBJECTIVE—Dietary and nutritional supplements are modulators of HDL cholesterol levels and production of apolipoprotein (apo) AI. Previously, in vitro treatment of hepatocyte cell lines with glucosamine increased apoAI production by stabilization of apoAI mRNA. The hypothesis is that the neutraceutical glucosamine, when given in conventional doses (1,500 mg/day) may increase apoAI and HDL cholesterol levels in subjects with diabetes and low HDL cholesterol.

RESEARCH DESIGN AND METHODS—Twelve subjects (three men and nine women) with type 1 (n = 2) and type 2 (n = 10) diabetes, aged 55 ± 12 years (mean ± SD), who had low HDL cholesterol (1.03 ± 0.20 mmol/l), were randomly assigned to a double-blind, placebo-controlled, cross-over trial of 500 mg glucosamine or placebo orally three times daily for 2 weeks, followed by a 4-week washout phase and a 2-week cross-over to the alternate therapy.

RESULTS—Fasting serum glucose, fructosamine, and total cholesterol remained stable during the drug and placebo phases. Glucosamine had no significant effect after therapy on serum levels of HDL cholesterol (from baseline of 1.02 ± 0.15 to 1.05 ± 0.16 mmol/l compared with placebo from 1.04 ± 0.21 to 1.06 ± 0.16 mmol/l) nor in changes in apoAI levels (from baseline of 147 ± 15 to 140 ± 126 mg/dl with glucosamine and from 146 ± 25 to 142 ± 17 mg/dl with placebo).

CONCLUSIONS—These observations suggest that glucosamine at commonly consumed doses does not have significant effects on glycemic control, lipid profile, or levels of apoAI in diabetic subjects after 2 weeks of supplementation.

Abbreviations: Apo, apolipoprotein

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?